Providing Safety and Effectiveness: Analytical Techniques for the Development of Gene and Cell Therapies and Quality Assurance

Background: Cell and gene therapies (CGTs) are groundbreaking therapies for complex diseases, but must be underpinned by robust analytical approaches for safety, efficacy, and quality, as they are complex biologically. Aim: This review aims to evaluate analytical approaches to CGT development and quality control with a focus on emerging technologies, regulatory considerations, and standardization challenges. Methods: The literature was searched comprehensively. Analytical methods like flow cytometry, qPCR, next-generation sequencing (NGS), and mass spectrometry were considered along with emerging technologies like single-cell RNA sequencing (scRNA-seq), microfluidics, and AI. Regulatory guidelines and standardization were also looked into. Results: Conventional methods like flow cytometry and qPCR provide good characterization and safety testing, while newer technologies, i.e., MS-based proteomics and AI-driven analytics, enhance precision and scalability. Standardized platforms, supported by NIST and public-private partnerships, form the basis of reproducibility. Challenges include raw material heterogeneity, scalability of high-throughput approaches, and regulatory harmonization. Multi-omics integration yields holistic perspectives but requires advanced bioinformatics. Conclusion: Standardized workflows, automation, AI, and multi-omics approaches are critical to surmount CGT development challenges, to ensure consistent quality and regulatory compliance.